INDOCO REMEDIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 328 INR | +0.75% |
|
-0.86% | -16.98% |
| Sales 2024 * | 18.19B 218M 17.37B | Sales 2025 * | 20.18B 242M 19.27B | Capitalization | 30.05B 360M 28.69B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.07B 12.86M 1.02B | Net income 2025 * | 1.65B 19.76M 1.57B | EV / Sales 2024 * | 1.65 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.49 x |
| P/E ratio 2024 * |
27.6
x | P/E ratio 2025 * |
18.2
x | Employees | 6,000 |
| Yield 2024 * |
0.61% | Yield 2025 * |
0.71% | Free-Float | 34.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Indoco Remedies Limited
More press releases
| 1 day | +0.55% | ||
| 1 week | -0.86% | ||
| Current month | -0.37% | ||
| 1 month | -3.61% | ||
| 3 months | -10.95% | ||
| 6 months | +1.25% | ||
| Current year | -16.98% |
1 week
323.05
335.75
1 month
323.05372.00
Current year
320.00414.35
1 year
308.80416.95
3 years
307.00529.70
5 years
133.10529.70
10 years
133.00529.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 26/03/04 | |
Pramod Ghorpade
DFI | Director of Finance/CFO | - | 01/09/21 |
| Chairman | 85 | 02/07/63 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 85 | 02/07/63 | |
| Director/Board Member | 63 | 31/12/81 | |
| Chief Executive Officer | 54 | 26/03/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 328 | +0.75% | 1 039 |
| 29/04/24 | 325.5 | -0.93% | 11,549 |
| 26/04/24 | 328.6 | +1.26% | 4,911 |
| 25/04/24 | 324.4 | -1.32% | 2,962 |
| 24/04/24 | 328.8 | -0.41% | 7,997 |
Delayed Quote Bombay S.E., April 30, 2024 at 06:07 am
More quotes
Indoco Remedies Limited is an India-based manufacturer of pharmaceutical products. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company offers medicines in multiple therapeutic categories, such as diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders and primary care medicine. Its products/brands include Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel among others. The Company caters to both domestic and international markets. Its subsidiaries include Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited.
Sector
Pharmaceuticals
Calendar
28/05/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
326
INR
Average target price
395.2
INR
Spread / Average Target
+21.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.47% | 664B | |
| +26.74% | 567B | |
| -6.33% | 354B | |
| +19.35% | 330B | |
| +4.23% | 286B | |
| +13.43% | 234B | |
| +4.71% | 199B | |
| -9.53% | 196B | |
| -4.04% | 148B |
- Stock Market
- Equities
- INDOCO Stock
- INDOCO Stock
